Evercore ISI Increases Twist Bioscience (NASDAQ:TWST) Price Target to $56.00

Twist Bioscience (NASDAQ:TWST) had its target price increased by Evercore ISI from $52.00 to $56.00 in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other analysts also recently issued reports about the company. TD Cowen increased their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a buy rating in a research report on Thursday, June 13th. Guggenheim assumed coverage on Twist Bioscience in a research report on Tuesday, June 4th. They set a buy rating and a $53.00 price target for the company. The Goldman Sachs Group increased their price target on Twist Bioscience from $45.00 to $55.00 and gave the company a buy rating in a research report on Tuesday, July 9th. Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an outperform rating in a research report on Monday, August 5th. Finally, Barclays decreased their target price on Twist Bioscience from $60.00 to $55.00 and set an overweight rating for the company in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $51.63.

Twist Bioscience Stock Up 1.3 %

Shares of Twist Bioscience stock opened at $43.34 on Tuesday. The company has a market cap of $2.54 billion, a PE ratio of -12.90 and a beta of 1.77. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $60.90. The business has a 50 day moving average price of $45.23 and a 200-day moving average price of $43.56.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same period last year, the company earned ($1.01) earnings per share. As a group, research analysts anticipate that Twist Bioscience will post -3.13 EPS for the current year.

Insider Transactions at Twist Bioscience

In other news, SVP Paula Green sold 3,310 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the transaction, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Paula Green sold 3,310 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the transaction, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dennis Cho sold 3,104 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $134,123.84. Following the sale, the insider now directly owns 75,289 shares of the company’s stock, valued at $3,253,237.69. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,232 shares of company stock valued at $1,834,749 over the last three months. Company insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently added to or reduced their stakes in the business. American International Group Inc. boosted its stake in Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after buying an additional 213 shares during the period. Caprock Group LLC boosted its stake in Twist Bioscience by 2.9% during the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after buying an additional 220 shares during the period. Arizona State Retirement System boosted its stake in Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after buying an additional 308 shares during the period. Massachusetts Financial Services Co. MA raised its position in Twist Bioscience by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after purchasing an additional 312 shares in the last quarter. Finally, CWM LLC raised its position in Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.